Protecting Our Planet

We seek to mitigate our impact on the environment, because the health of the planet is inherently linked to the health of those who inhabit it. We do this by focusing on:

Climate Action and Resilience. Global temperatures are increasing at an alarming rate, largely because of greenhouse gases (GHGs), which trap heat in the atmosphere. We have ambitious targets to reduce our absolute scope 1 and 2 GHG emissions—our operational emissions—by 25% by 2025 and by 46% by 2030 (vs. 2019), and to reduce our absolute scope 3 emissions—indirect emissions that occur in our value chain—by 25% by 2030 (vs. 2020). Our GHG emissions targets were validated by the Science Based Targets initiative (SBTi), demonstrating that our commitments are ambitious and support global efforts to tackle climate change.

Responsible Use of Natural Resources. We have a responsibility to conserve resources, including water and materials used in the manufacturing, packaging and delivery of our products. Our sites evaluate water conservation opportunities and those in areas projected to be in water stress have formalized water conservation programs. In 2022, we reduced our water withdrawal by 17% in areas projected to be in water stress (vs. 2020).

Effluents and Waste. We proactively prevent and address waste at various stages of our operations. We require our sites to establish and implement initiatives for minimizing hazardous and non-hazardous waste and implement reuse and recycling programs.

Pharmaceuticals in the Environment. We assess and mitigate the environmental impact of pharmaceutical ingredients, including Antimicrobials, from our operations and work with our supply chain to do the same. Our sites are required to follow emission and effluent-related requirements, and we have a risk-based approach for understanding and controlling the discharge of active pharmaceutical ingredients (API) in wastewater from our facilities.

ESG Progress Report

Find out more


Share this article:

You might also be interested

Meet Teva USA’s HBA Rising Star and Luminary

Meet Teva USA’s HBA Rising Star and Luminary

Why Diversity in Clinical Trials is So Important

Why Diversity in Clinical Trials is So Important

Meet Our
People

Meet our People: Merle Goddard

Meet our People: Merle Goddard

Teva receives the Equality 100 award on Human Rights Campaign Foundation's Annual Scorecard Assessin...

Teva receives the Equality 100 award on Human Rights Campaign Foundation's Annual Scorecard Assessing LGBTQIA+ Workplace Equality

Behind the
Numbers

“Mental health care is not a one stop deal": How Teva is Combining Medicine and Ongoing Support

“Mental health care is not a one stop deal": How Teva is Combining Medicine and Ongoing Support